461 results on '"Vanwolleghem, Thomas"'
Search Results
2. Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD
3. JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2
4. Spleen stiffness measurement by vibration-controlled transient elastography at 100 Hz for non-invasive predicted diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a modelling study
5. Diagnostic criteria and long-term outcomes in AIH-PBC variant syndrome under combination therapy
6. An open-label randomised-controlled trial of azathioprine vs. mycophenolate mofetil for the induction of remission in treatment-naive autoimmune hepatitis
7. Opportunistic screening using point-of-care testing leads to successful linkage to care of HBV-infected migrant populations in a low endemic country
8. Predictors of hepatic flares after nucleos(t)ide analogue cessation – Results of a global cohort study (RETRACT-B study)
9. Prevalence of chronic HCV infection in EU/EEA countries in 2019 using multiparameter evidence synthesis
10. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
11. Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial
12. Differential Relapse Patterns After Discontinuation of Entecavir vs Tenofovir Disoproxil Fumarate in Chronic Hepatitis B
13. Assessment of portal hypertension severity using machine learning models in patients with compensated cirrhosis
14. Viral clade is associated with severity of symptomatic genotype 3 hepatitis E virus infections in Belgium, 2010–2018
15. WED-372 Downregulation of soluble FASLG as a potential mechanism of enhanced immune-related clearance of infected hepatocytes induced by JNJ-73763989 in HBeAg-negative virologically suppressed chronic hepatitis B patients
16. WED-426 From kitchen to table: unravelling hepatitis E virus inactivation in pork meat products
17. OS-096-YI Spleen stiffness measurement by transient elastography at 100 Hz refines the non-invasive diagnosis of clinically significant portal hypertension in compensated advanced chronic liver diseasefinal results of a european multicenter study
18. FRI-043 A multi-center randomized controlled study of primary prevention of esophageal variceal bleeding in cirrhotic patients treated with HVPG-guided therapy or standard heart rate-guided therapy: an interim analysis of the PORTHOS trial
19. FRI-406 Real world outcomes of hepatitis delta patients with mild or moderate fibrosis
20. WED-441-YI Precise estimation of national HBV prevalence: the importance of double hepatitis B surface antigen and hepatitis B core antibody testing in low endemic countries
21. SAT-051 The clinical relevance of prior bariatric surgery in alcohol-related liver disease in a nationwide belgian liver transplant population
22. WED-281-YI A non-invasive score model for prediction of significant fibrosis and fibrotic metabolic dysfunction-associated steatohepatitis based on serum biomolecules
23. SAT-337 Serum levels of IgA inform on the transcriptomic architecture of the liver and predict hepatocellular carcinoma in chronic viral hepatitis patients
24. SAT-134 Paired assessment of the hepatic venous pressure gradient with the push-wedge versus balloon-occlusion technique: impact of intrahepatic collaterals
25. WED-379 Intrahepatic changes in immunologic and virologic markers during siRNA JNJ-73763989 (JNJ-3989) based treatment of chronic hepatitis B (CHB) patients: imaging mass cytometry (IMC) analyses from the INSIGHT study
26. TOP-401-YI Improvement of liver stiffness during nucleo (s)tide analogue treatment in patients with chronic hepatitis B and advanced fibrosis is not associated with a reduction in hepatocellular carcinoma risk
27. Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease
28. Ten years countdown to hepatitis C elimination in Belgium: a mathematical modeling approach
29. Assessing the efficacy and safety of mycophenolate mofetil versus azathioprine in patients with autoimmune hepatitis (CAMARO trial): study protocol for a randomised controlled trial
30. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
31. Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study)
32. Long‐term outcome of hepatitis delta in different regions world‐wide: Results of the Hepatitis Delta International Network.
33. Limited Sustained Remission After Nucleos(t)ide Analog Withdrawal: Results From a Large, Global, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study).
34. Humoral immunity in hepatitis B virus infection: Rehabilitating the B in HBV
35. Diagnostic criteria and long-term outcomes in AIH-PBC variant syndrome under combination therapy
36. Patient profiled data for treatment decision-making:valuable as an add-on to hepatitis C clinical guidelines?
37. Hepatitis B core-specific memory B cell responses associate with clinical parameters in patients with chronic HBV
38. Diet Reversal and Immune Modulation Show Key Role for Liver and Adipose Tissue T Cells in Murine Nonalcoholic Steatohepatitis
39. Progression of the FIB-4 index among patients with chronic HCV infection and early liver disease
40. Spleen stiffness measurement by vibration-controlled transient elastography at 100 Hz for non-invasive predicted diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a modelling study
41. A Multifaceted Approach for Evaluating Hepatitis E Virus Infectivity In Vitro: Cell Culture and Innovative Molecular Methods for Integrity Assessment
42. Hepatic safety and efficacy of immunomodulatory drugs used in patients with autoimmune hepatitis
43. The elimination of hepatitis D as a public health problem: Needs and challenges
44. Transarterial Chemoembolization With Drug-Eluting Beads Versus Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Outcomes From a Multicenter, Randomized, Phase 2 Trial (the TRENDY Trial)
45. Durability of Response After Hepatitis B Surface Antigen Seroclearance During Nucleos(t)ide Analogue Treatment in a Multiethnic Cohort of Chronic Hepatitis B Patients: Results After Treatment Cessation
46. Predictors of severe flares after nucleos (t)ide analogue cessation-results of a global cohort study (RETRACT-B study)
47. Intrahepatic characterization of virological and immunological markers in two distinct populations of chronic hepatitis B: baseline assessment of core liver and fine needle aspiration biopsies from the investigational INSIGHT study
48. Natural history of patients with NAFLD-associated compensated advanced chronic liver disease stratified according to severity of portal hypertension
49. Utility of partial cure as an end point after nucleos (t)ide analogue withdrawal among chronic hepatitis B patients (RETRACT-B study)
50. Platelet, elastography, age, sex and etiology for hepatocellular carcinoma surveillance in patients with advanced chronic liver disease: Please algorithm
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.